Scientists scan brains to see if new drug calms ALS inflammation
NCT ID NCT04066244
Summary
This study tested an experimental drug called BLZ945 in people with ALS (amyotrophic lateral sclerosis). The main goal was to see if the drug could safely reduce inflammation from specific brain cells (microglia) and to find the right dose. Researchers used special brain scans (PET) to measure changes in inflammation before and after treatment in 28 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Novartis Investigative Site
Turku, 20520, Finland
-
Novartis Investigative Site
Stockholm, 14186, Sweden
-
Yale University School of Medicine
New Haven, Connecticut, 06520-8048, United States
Conditions
Explore the condition pages connected to this study.